share_log

中基長壽科學:中期報告 2024

ZHONG JI LS: Interim Report 2024

HKEX ·  Sep 27 17:00

Summary by Futu AI

中基長壽科學集團有限公司(「中基長壽」)於二零二四年上半年繼續從事長壽科學業務、借貸及金融諮詢業務、證券及其他投資以及物業投資。期內,集團收益為42,403,000港元,較去年同期的29,911,000港元有所增加。然而,集團於期內錄得虧損917,000港元,而去年同期則錄得溢利1,938,000港元。集團的虧損主要由於匯兌損失及投資公平值的變動。截至二零二四年六月三十日,集團資產淨值為432,113,000港元。集團於報告期內並無宣派任何股息(二零二三年六月三十日:無)。此外,集團於報告期內完成股份認購,共發行91,088,258股新股份,籌集約19,400,000港元淨額,用於擴張現有長壽科學業務及新生物醫藥產品貿易業務。報告期後,集團並無發生任何重大事件。
中基長壽科學集團有限公司(「中基長壽」)於二零二四年上半年繼續從事長壽科學業務、借貸及金融諮詢業務、證券及其他投資以及物業投資。期內,集團收益為42,403,000港元,較去年同期的29,911,000港元有所增加。然而,集團於期內錄得虧損917,000港元,而去年同期則錄得溢利1,938,000港元。集團的虧損主要由於匯兌損失及投資公平值的變動。截至二零二四年六月三十日,集團資產淨值為432,113,000港元。集團於報告期內並無宣派任何股息(二零二三年六月三十日:無)。此外,集團於報告期內完成股份認購,共發行91,088,258股新股份,籌集約19,400,000港元淨額,用於擴張現有長壽科學業務及新生物醫藥產品貿易業務。報告期後,集團並無發生任何重大事件。
Zhong Ji LS Group Limited ("Zhong Ji LS") continued to engage in zhong ji ls business, lending and financial consulting business, securities and other investments, and property investments in the first half of 2024. During the period, the group's revenue was HK$42,403,000, an increase from HK$29,911,000 in the same period last year. However, the group incurred a loss of HK$917,000 during the period, compared to a profit of HK$1,938,000 in the same period last year. The group's loss was mainly due to exchange losses and changes in the fair value of investments. As of June 30, 2024, the group's net assets were HK$432,113,000. The group did not declare any dividends during the reporting period (June 30, 2023: none). In addition, the group completed a share subscription during the reporting period, issuing a total of 91,088,258 new shares, raising approximately HK$19,400,000 net proceeds for expanding existing zhong ji ls business and new biomedical product trading business. After the reporting period, the group did not experience any significant events.
Zhong Ji LS Group Limited ("Zhong Ji LS") continued to engage in zhong ji ls business, lending and financial consulting business, securities and other investments, and property investments in the first half of 2024. During the period, the group's revenue was HK$42,403,000, an increase from HK$29,911,000 in the same period last year. However, the group incurred a loss of HK$917,000 during the period, compared to a profit of HK$1,938,000 in the same period last year. The group's loss was mainly due to exchange losses and changes in the fair value of investments. As of June 30, 2024, the group's net assets were HK$432,113,000. The group did not declare any dividends during the reporting period (June 30, 2023: none). In addition, the group completed a share subscription during the reporting period, issuing a total of 91,088,258 new shares, raising approximately HK$19,400,000 net proceeds for expanding existing zhong ji ls business and new biomedical product trading business. After the reporting period, the group did not experience any significant events.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.